

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRA737,Aphidicolin,Momelotinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Attacking drug-resistant tumors with Sierra’s struggling CHK1 blocker
Details : Scientists found that combining the drug with another protein inhibitor leads to insurmountable DNA damage that causes cancer cells to die.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2020
Lead Product(s) : SRA737,Aphidicolin,Momelotinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
